Secukinumab Long-Term Reduction of Radiographic Progression in Ankylosing Spondylitis

cosentyx article
cosentyx article
For patients with ankylosing spondylitis, secukinumab may reduce radiographic progression and remain effective in the long-term.
This article is part of Rheumatology Advisor’s 2017 in-depth coverage of ACR, which took place in San Diego, CA. Our staff will be reporting on the latest treatment advancements and research initiatives for spondyloarthritis. Click here to read more of Rheumatology Advisor‘s conference coverage.

SAN DIEGO — For patients with ankylosing spondylitis (AS), secukinumab may reduce radiographic progression and remain effective in the long term, according to trial results presented at the American College of Rheumatology 2017 Annual Meeting, held November 3-8.

In the MEASURE 1 trial ( Identifier: NCT01863732), 165 patients were randomly selected to receive secukinumab or placebo. Patients in the secukinumab trial were administered a 10 mg/kg intravenously loading dose at baseline, week 2, and week 4, followed by 150 mg secukinumab subcutaneously (SC; n=87) or 75 mg secukinumab SC (n=78) at week 16 for nonresponders or week 24 for responders. Two independent readers examined lateral radiographs of the cervical and lumbar spine using the modified Stoke Ankylosing Spondylitis Spinal Scar (mSASS) at baseline, week 104, and week 204.

Related Articles

The average change in mSASS from baseline to week 208 was lower with secukinumab 150 mg compared with secukinumab 75 mg (1.2±3.91 vs 1.7±4.70). No radiographic progression was observed in 73% and 79% of patients who had received secukinumab 150 mg and 75 mg, respectively. The average change in mSASS at week 208 was higher in men vs women in patients with elevated vs normal baseline levels of high-sensitivity C-reactive protein, and in patients with vs without baseline syndesmophytes. Efficacy was sustained through week 208, with lower-efficacy responses in patients who had received secukinumab 75 mg.

“Secukinumab 150 mg demonstrates lower radiographic progression vs 75 mg at 4 years,” the researchers concluded. “These 4-year results confirm the sustained efficacy and known safety profile of secukinumab.”

Visit Rheumatology Advisor’s conference section for our in-depth focus on spondyloarthritis at ACR 2017.


Braun J, Baraliakos X, Deodhar AA, et al. Secukinumab demonstrates low radiographic progression and sustained efficacy through 4 years in patients with active ankylosing spondylitis. Presented at: American College of Rheumatology (ACR)/Association of Rheumatology Health Professionals (ARHP) Annual Meeting; November 3-8, 2017; San Diego, CA. Abstract 3L.